What Is Health Economics and Outcomes Research (HEOR)? A Guide for Clinical Research Sites
If you have experience managing or working at a clinical research site it is very likely you've heard the term Health Economics and Outcomes Research or “HEOR” mentioned in conversation with sponsors or in protocol documents. It may even sound a bit too abstract compared to the tangible site schedules and source documents. Though HEOR directly touches your work more than you know. Here we break down what HEOR actually is, why it matters to sponsors and payers and how it connects to the day to day operations of a clinical trial site.
What Health Economics and Outcomes Research (HEOR) Means, in Plain Terms
Health Economics and Outcomes Research (HEOR) is the field that studies if a medical treatment or new investigational product (IP) is worth how much it costs. This is not whether the treatment or IP works as it is intended, but whether it can be marketed at a cost that is attainable by enough people compared to alternative treatments. This is evaluated by three intersecting questions:
Clinical Effectiveness - Does the treatment improve health outcomes
Economic Value - How much does it cost relative to the benefits it provides
Real-World Impact - Outside the controlled conditions of a trial, does it perform the same
The evidence found during HEOR research is used by insurers, government payers, health systems, and regulatory bodies. This data is used to inform decisions about which treatments are covered, at what price, and for which patients.
Why Sponsors Care So Much About HEOR
HEOR is important to determine the commercial success of a new treatment. A drug or device can advance through each clinical trial phase and meet every regulatory requirement but fall flat in the marketplace if payers won't reimburse it. To ensure commercial success, sponsors are increasingly designing HEOR considerations into early trial and planning stages as opposed to waiting till after all trials are completed before beginning HEOR.
This is seen in a few different areas of trial design:
Patient-reported outcomes (PROs) are built into protocols to capture quality-of-life data, not just clinical endpoints like tumor size or lab values.
Real-world evidence (RWE) studies are increasingly run alongside or after traditional trials, often using registry data or electronic health records.
Health-related quality of life (HRQoL) instruments and quality-adjusted life years (QALYs) , a standard metric combining length and quality of life into a single value, are used to model cost-effectiveness. (Note: QALY methodology and acceptance vary by country and payer)
For research sites and clinical trial staff, this means the paperwork burden isn't only about safety and efficacy anymore. PRO questionnaires, caregiver surveys, and health-utility assessments are HEOR-driven data points, and how carefully your site administers and documents them affects the strength of the sponsor's economic case down the line.
How HEOR Connects to Site-Level Data Quality
With a growing emphasis on HEOR it is showing up more and more in the site operations, PRO instruments are regularly administered and must be done so consistently to ensure economic modeling data is accurate. Seemingly minor items such as staff wording questions differently, surveys or other instruments completed outside of the required time window, or missing follow up data can result in unreliable HEOR data. This can have ripple effects ultimately impacting the payers converge decision of the treatment years down the road.
This is where ALCOA-C principles are important to ensure that the data is attributable, legible, contemporaneous, original, and accurate. The HEOR data points deserve the same rigor as any primary clinical endpoint, even though they can feel like extra paperwork in the middle of a busy visit.
HEOR and Site Selection
Site selection by sponsors is not just based on their Good Clinical Practice (GCP) track record or patient recruitment speed and retention. Increasingly, sponsors are considering the diversity of the site's patient population against real-world demographics. These demographics all play into the HEOR analysis.
Independent physician practices and community-based sites, including many across Texas and New Mexico, often serve exactly the kind of real-world, less-controlled patient population that strengthens a sponsor's outcomes research, compared to large academic centers with more homogenous patient pools. Understanding this and documenting site cultural competencies can be a genuine talking point for a site pursuing sponsor relationships or working with a Site Management Organization (SMO).
Common HEOR Study Types You Might Encounter
Sites don't typically run HEOR studies themselves, but it helps to recognize the terminology when it appears in protocols or sponsor communications:
Cost-effectiveness analysis (CEA): Compares the cost and outcomes of a treatment against an alternative, often expressed as cost per QALY gained.
Budget impact analysis (BIA): Models the financial effect of adopting a new treatment on a health system or payer's budget.
Retrospective database studies: Use existing claims or EHR data to study outcomes and costs after the fact, without new patient visits.
Prospective observational studies: Follow patients in real-world (non-randomized) settings, often layered onto or following a traditional trial.
Patient registries: Long-term, often multi-site data collection efforts that feed both safety monitoring and outcomes research.
If your site is asked to participate in any of these, the underlying expectations around data completeness and consistency remain the same as in a traditional interventional trial.
Bringing It Back to the Site Level
HEOR can feel like an abstract idea that is discussed in conference rooms far away from the clinical trial site and exam room. Though the decisions at those meetings rely on the site level information and data obtained. This makes it important for all clinical staff to value and protect the HEOR data as if it were the clinical data for the same trial.
Comments